Defining the Properties of the OS-33 Osteosarcoma Cell Line and Effects of mTORC1 Inhibition by Rapamycin by Palmer, Mykayla
University of South Dakota 
USD RED 
Honors Thesis Theses, Dissertations, and Student Projects 
Spring 2019 
Defining the Properties of the OS-33 Osteosarcoma Cell Line and 
Effects of mTORC1 Inhibition by Rapamycin 
Mykayla Palmer 
University of South Dakota 
Follow this and additional works at: https://red.library.usd.edu/honors-thesis 
Recommended Citation 
Palmer, Mykayla, "Defining the Properties of the OS-33 Osteosarcoma Cell Line and Effects of mTORC1 
Inhibition by Rapamycin" (2019). Honors Thesis. 60. 
https://red.library.usd.edu/honors-thesis/60 
This Honors Thesis is brought to you for free and open access by the Theses, Dissertations, and Student Projects 
at USD RED. It has been accepted for inclusion in Honors Thesis by an authorized administrator of USD RED. For 







DEFINING THE PROPERTIES OF THE OS-33 OSTEOSARCOMA CELL LINE 
 


























A Thesis Submitted in Partial Fulfillment 
Of the Requirements for the 




Department of Basic Biomedical Sciences 











The members of this Honors Thesis Committee appointed 
to examine the thesis of Mykayla Palmer 







Dr. Jianning Tao 
Director of the Committee 
Cancer Biology and Immunotherapies Group, Sanford Research 
Assistant Professor Department of Pediatrics at Sanford School of Medicine, University 







Ashley VanCleave, B.S. 








Dr. Fang Fang 



















Defining the Properties of the OS-33 Osteosarcoma Cell Line and Effects of mTORC1 




Director: Dr. Jianning Tao, PhD 
 
 
Osteosarcoma (OS) is the predominant form of primary malignant bone cancer 
and is most commonly found in children and adolescents. OS is associated with high 
mortality rates and poor prognosis for the majority of patients [1]. Within the last few 
decades, there has been little to no improvement in patient outcome. Current treatment 
methods include surgical excision of the tumor alongside chemotherapy. However, high 
rates of metastasis still persist, which is considerably more difficult to target with 
chemotherapy or to remove by surgery [2].  
Thanks to recent advances in molecular genetics and medicine, we can better 
understand OS and the properties of the cancer in order to develop an improved treatment 
plan. We examined a novel Patient Derived Xenograft (PDX) cell line, OS-33. While 
little is known about OS-33, preliminary data indicates sensitivity to the drug rapamycin, 
which is suggested to inhibit the mammalian target of rapamycin complex 1 (mTORC1) 
pathway [3]. The mTORC1 pathway is upregulated in many OS patients, which 
highlights this pathway as a new and promising therapeutic target [3]. The inhibition of 
mTORC1 signaling by rapamycin was studied to determine how it suppresses cell 
migration, invasion, proliferation, and stem cell differentiation in the OS-33 cell line. 
This study underlines the importance of the mTORC1 signaling pathway and provides 
evidence for potential drugs which target OS. 
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Defining the Properties of the OS-33 Osteosarcoma Cell Line and Effects of 
mTORC1 Inhibition by Rapamycin 
 
Osteosarcoma (OS) is a primary malignant bone cancer caused by the aberrant 
proliferation of immature bone tissue [4]. Often, the tumor is found in long bone tissues, 
specifically in the tibia, humerus, and femur [5]. 3.1 cases per million of OS occur each 
year and generally affect children with immature osteoid tissues [6]. OS is a rare, but 
aggressive cancer. According to previous literature, the survival rate after 5 years is as 
low as 61.6% [7]. 
Historical treatment methods for OS focuses on local therapy, such as surgical 
excision of the bone tumor; however, OS is known to have high rates of tumor 
metastasis, which is difficult to control or prevent. Nearly 30% of patients who receive 
surgical excision treatment were diagnosed with a metastatic tumor [8]. Most commonly, 
tumor metastasis occurs in the lungs [8]. New clinical trials show that a combination of 
drug therapy and chemotherapy will increase patient survival rates [9]. By using 
combined methods, there was a higher success rate for removal the primary tumor and 
preventing metastasis [2]. However, better regimens and new drugs are required for the 
group of patients with metastatic osteosarcoma at diagnosis. 
In order to implement combination therapies, it is essential to understand the 
molecular mechanisms behind which OS operates. The mTORC1 pathway is a kinase 
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cascade pathway which has been found to have sporadic gene mutations in OS, called 
genetic drivers [10]. These drivers are found in 24% of OS patients and allow for 
targeting of the kinases with an mTORC1 inhibitor, such as rapamycin [10, 11]. It is 
imperative to understand how rapamycin and other treatments inhibit the mTORC1 
pathway in order to target osteosarcoma tumors and metastasis. Doxorubicin, which is a 
common chemotherapy drug used in current treatment methods, was tested in conjunction 
with rapamycin as a combination therapy treatment [12]. Due to high levels of 
doxorubicin toxicity, only small doses may be used when treating OS patients [12]. This 
presents the need for other drugs to be used in conjunction with doxorubicin in order to 
limit toxicity. By adding rapamycin to doxorubicin, the possibility for a more efficient 
and safer treatment method can be assessed.  
  This study focuses on the inhibition of mTORC1 signaling by rapamycin to 
determine if inhibitor suppresses cell migration, invasion, proliferation, and stem cell 
differentiation. Specifically, the experiments explored the OS-33 cell line, which is a 
novel line derived from a human PDX. The purpose of this study is to better understand 
the characteristics of OS-33. After obtaining preliminary results, synergistic combination 
therapy treatments with doxorubicin were implemented to better target osteosarcoma and 
metastases.  
The properties of OS-33 were defined by using a series of in vitro experiments 
involving treatment of the OS-33 cell line with or without rapamycin at various 
concentrations (0, 0.1, 1, 10 ng/mL, etc.). These experiments included, but were not 
limited to: Western blot analysis, scratch assay, proliferation assay, trans-well 
migration/invasion assay, adipocyte differentiation, and osteoblast differentiation. Our 
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study suggests that OS-33 cell growth is inhibited by rapamycin treatment and that 
combination therapies downregulate mTORC1 expression. Our results as a whole help us 
to define the properties of the OS-33 cell line and to better understand OS. This study 
also underlines the importance of targeting osteosarcoma with combination therapy in 
















OS-33 Cell Line 
The OS-33 OS samples were derived from a Patient Derived Xenograft (PDX) tumor 
obtained from Dr. Peter Houghton at University of Texas Health Sciences in San 
Antonio, TX. The tissue sample was originally generated from a human OS tissue sample 
and used to develop into a novel cell line in Dr. Jianning Tao’s lab. OS-33 was cultured 
in MEM Alpha Modification (1X) Medium (with L-Glutamine, Ribonucleosides, 
Deoxyribonucleosides) plus 10% Fetal Bovine Serum and 1% Penicillin-Streptomycin. 
Medium was obtained through GE Healthcare Life Sciences HyClone laboratories. OS-
33 cells were stored in incubation units at 37°C with 5% CO2 release and medium 
changes were conducted every 3-4 days. Unless stated otherwise, cells were incubated in 
this manner for both experiments and culturing. Cell lines were grown in 100 mm Fisher 
Scientific tissue culture dishes. Once grown to complete confluency, cells were passaged 
by rinsing with Phosphate-Buffered Saline (PBS, 0.01 mol/L, pH 7.4), adding 0.25% 
Trypsin-EDTA (1X) for 3-5 minutes in order to dissociate cells from the bottom of the 





C2C12 and L2 Control Cell Lines 
The L2 and C2C12 mouse cell lines were used as control cell lines in experiments. All 
cell lines listed were cultured in MEM Alpha Modification (1X) Medium plus 10% Fetal 
Bovine Serum, and 1% Penicillin Streptomycin as described previously. Unless otherwise 
stated, cell lines were cultured in this manner and incubated at 37°C with 5% CO2 
release. Medium changes were conducted as necessary. 
 
Rapamycin Storage, Preparation, and Treatment 
The rapamycin stock was stored in a -80°C freezer. The  
drug was dissolved in 100% ethanol to make 10 mg/mL and further diluted to several 
varying µg/mL stock solutions for usage in experiments. In control groups, the ethanol 
served as the vehicle and a corresponding amount was added. These were stored in a -
20°C freezer and used for treating cells with a 1:1000 dilution into medium. The dosage 
and timeframe of rapamycin treatment in our experiments was described in the result 
section to define how treatment affects the OS-33 cell line migration, proliferation, and 
translation.  
 
Karyotype Analysis  
OS-33 cells were frozen and sent for karyotype analysis, which was conducted by Dr. 
Patricia Crotwell-Leiferman and Alan Ross in core of Sanford Imagenetics of Sanford 




Western Blot Analysis 
Four 100 mm plates of OS-33 cells were grown for 24 hours with 0, 0.1, 1, and 10 ng/mL 
rapamycin treatment. After 24 hours, the treated OS-33 plates were rinsed with PBS. 
Then, cells were lysed with a lysis buffer consisting of 750 µL SDS, 675 µL PBS, and 75 
µL DTT. Immediately after addition of the buffer, plates were “scraped” with a Fisher 
Scientific cell scraper to collect the proteins. Using a pipette, the contents of the plate 
were retrieved and stored in a labeled 1.5 mL Microcentrifuge Tube. This process was 
repeated for all treated OS-33 plates, ensuring not to cross contaminate. Vials containing 
the OS-33 cell lysates were immediately heated at 95°C for 5 minutes before being frozen 
in a -20°C freezer until needed for Western blot analysis. 
Once ready for analysis, the rapamycin-treated OS-33 protein lysates were removed from 
the freezer and heated at 95°C for 5 minutes. Lysates were then sonicated and returned to 
the 95°C heater. Using a gel electrophoresis instrument and protein lysates with 4–20% 
Mini-PROTEAN® TGX™ Precast Protein Gels, the previously collected OS-33 proteins 
were loaded with a pipette tip and electrophoresis was conducted at 200 V for 45 
minutes. A dual color ladder was used for indication of sizes and locations of proteins in 
the gel. After running the gel, the membrane was placed in methanol solution and 1X 
Transfer Buffer. A PVDF membrane was loaded into a semi-dry Bio-Rad Trans-blot 
apparatus and protein samples were transferred. The membrane was then probed with 
mouse anti-Vinculin antibody, S6 antibody, and pS6 antibody. A secondary antibody was 
added for one hour. The secondary antibody was anti-rabbit for the anti-Vinculin 
antibody and anti-mouse for the pS6 and s6 antibodies. Membranes were treated with 0.5 
mL Luminal/Enhancer Solution and 0.5 mL Super Signal West Pico Stable Peroxide 
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Solution before imaging on a UVP imager. Density and relative expression level were 
calculated and compared using NIH Image J.   
 
Colony Formation Assay 
OS-33 cells were counted using trypan blue and a Countess cell counter. Using full 
medium treated with 0.1 ng/mL rapamycin, 1 ng/mL rapamycin, or 100% ethanol (0 
ng/mL rapamycin), cells were diluted to 1,000 cells/mL and seeded into a 6-well Fisher 
Scientific tissue culture plate. Then, OS-33 cells were monitored over several days for 
colony formation. After a 16-day period, cells were rinsed with PBS, fixed with 10% 
Formalin, stained with crystal violet, and imaged under a IX70 microscope.  
 
Scratch Assay 
OS-33 cells were seeded from a 100 mm tissue culture plate into a 6-well Fisher 
Scientific tissue culture plate and grown to complete confluency. A sterile p1000 pipette 
tip was scratched slowly along the bottom each of the six wells to create a uniform 
“scratch” or “wound” in the cells. Immediately after scratching, cells were rinsed five 
times with PBS in order to remove cells which were displaced from the plate after 
scratching. Full medium was added to three wells and full medium with 1 ng/mL 
rapamycin was added to three wells. Then, the cells were imaged for initial wound size. 
Directly after imaging, the plate was returned to incubation overnight. Photographs were 
taken again at the initial wound sites and compared to the initial wound sizes in order to 
measure overall migration and proliferation of OS-33 cells. NIH Image J (NIH, Bethesda, 
MD, USA) was used to measure closure of the wound.  
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Trans-well Migration Assay  
Using an 8-µm Fisher Scientific pore-sized chamber system, a trans-well migration assay 
was completed to test the overall ability of OS-33 cells to travel through a semi-porous 
membrane towards a chemoattractant. The bottom chamber was filled with full medium 
(MEM-alpha plus 10% Fetal Bovine Serum and 1% Penicillin-streptomycin) and 1 
ng/mL rapamycin or 100% ethanol. Prior to setting up the migration assay, cells were 
placed in serum-free medium overnight in order to make them more susceptible to travel 
towards the chemoattractant and to prevent cellular proliferation. The serum-free cells 
were treated with 1 ng/mL rapamycin or 100% ethanol and seeded at approximately 
20,000 cells per well into the upper chamber above the membrane. Cells were returned to 
incubation for 24 hours and then fixed in 10% formalin and stained with crystal violet 
(Fisher Scientific, C581-25) the next day. The upper chamber was cleaned with PBS and 
Q-tip before imaging with an IX70 microscope for qualitative results. After this, 33% 
acetic acid was added to the stained cells, removing the stain from the cells. After 
removing the crystal violet, 100 µL of the solution was moved into a new 96-well Falcon 
plate. An optical density (OD) was taken at 570 nm on the Cytation3 and the results were 
analyzed for quantification. 
 
Trans-well Invasion Assay  
The invasion assay was conducted exactly as described in the trans-well migration assay 
previously, except there was a 0.2 mg/mL matrigel (Fisher Scientific, CB354248) 
covering the membrane.  
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Adipocyte Differentiation with Rapamycin Analysis 
OS-33 was grown to 90% confluency in a 12-well Fisher Scientific plate and were treated 
with adipocyte-inducing medium to induce cell differentiation into adipocytes in the OS 
cell line. Medium was prepared by addition of 1 µL/mL of 125X IBMX, 1 µL/mL of 1 
mM Dexamethasone, 1 µL/mL of 10 mg/mL Insulin, and 1 µL/mL of 1mM 
Rosiglitazone to full MEM-alpha medium. This medium was used only for Day 0 of 
treatment. In addition, 1 µL/mL of rapamycin was added to treated wells. In the medium 
without rapamycin 1 µL/mL of 100% ethanol was added for control. Full MEM-alpha 
medium without modification was used for control in untreated OS-33 cells. Cells were 
seeded into a 12-well Fisher Scientific plate. On Day 0, cells were treated with the 
prepared mediums. Cells were returned to incubation until day 4. Then, a medium change 
was completed using full medium with 1 µL/mL of 10 mg/mL Insulin and 1 µL/mL of 1 
mM Rosiglitazone. Medium change was completed every 3 days for 14 days, being 
careful to never cross contaminate. At the end of the 14-day period, cells were fixed with 
10 % formalin and stained with Oil Red-O and hematoxylin counter stain. Cells were 
imaged for adipocyte differentiation under an IX70 microscope and counted using NIH 
Image J. 
 
Osteoblast Differentiation Analysis  
Cells were grown to 90% confluency in a 12-well Fisher Scientific plate and treated with 
osteoblast-inducing differentiation medium (control cells were grown in full MEM alpha 
medium). This medium was prepared by adding 1 µL/mL of 14.5 mg/mL (50 mM, 
1000X) ascorbic acid, 1 µL/mL of 100 µM Dexamethasone, and 10 µL/mL of 1 M BGP 
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(100X) to MEM Alpha Medium.  Osteoblast-differentiation-inducing medium was added 
to OS-33 cells and an L2 control cell line. The osteoblast-differentiation-inducing 
medium and MEM Alpha Modification growth medium were changed every three days 
for 14 days. On the 14th day, fixation with 10% formalin and Alizarin Red staining 
(Sigma A5533, MW: 342.26, pH 4.2) was completed. Results were imaged under an 
IX70 microscope. After initial results, 1 µL/mL of BMP-2 was added to the osteoblast 
medium to further induce differentiation and C2C12 cells were used as a control cell line 
as opposed to L2. C2C12 was used because of the capability for the cell line to 
differentiate when BMP-2 was added to medium as described in previous literature [13]. 
BMP-2 was diluted with 5% DMSO. 
 
Cell Proliferation with Rapamycin and Doxorubicin 
OS-33 cells were rinsed with PBS and treated with 0.25% Trypsin-EDTA (1X) in a 10 
mm tissue Fisher Scientific culture plate to remove cells from the plate. Cells were then 
counted using trypan blue dye and a Countess cell counter. Several concentrations of 
rapamycin were added by 1 µL/mL to full medium in order to produce 0, 3.125, 6.25, 
12.25, 25, 50, and 100 ng/mL treatments. Cells were seeded using the prepared 
rapamycin-treated full medium in a 96-well Fisher Scientific plate at 6,500 cells/well. 
After 24 hours, a medium change was completed using the corresponding rapamycin-
treated full medium. At 45 hours, 10 µL of CCK-8 was added to each well. The CCK-8 
treated cells were returned to incubation for 3 hours. At 48 hours, the concentration of 
cells was counted with an OD on the Cytation3 instrument. Results were analyzed and 
proliferation was compared between the differing rapamycin concentrations. These same 
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protocols were used for testing proliferation with doxorubicin and doxorubicin/rapamycin 
combination therapy. Doxorubicin was diluted with 0.5 % DMSO and tested at 0, 1.5625, 
3.125, 6.25, 12.5, and 50 µM. When testing combination therapy using doxorubicin and 
rapamycin, a 1:2 doxorubicin to rapamycin constant-ratio drug treatment was 
implemented in order to test the synergistic effects of the two drugs. Specifically, 
concentrations of 0:0, 1.5625:3.125, 3.125:6.25, 6.25:12.5, 12.5:25, 25:50, and 50:100 
µM:ng/mL were used. Corresponding amounts of ethanol and DMSO, respectively, were 
used as controls.  
 
Statistical Analysis 
Microsoft Excel Sheets were used for statistical calculation and formation of graphs. A 
two-tailed Student’s t-test was used to compare treatment groups in quantifications of 
Western blot, proliferation assays, scratch assay, trans-well migration and invasion 
assays. Statistical significance was determined at *P<0.05, **P<0.01, and ***P <0.001 

















Characteristics of the OS-33 Cell Line 
 






Figure 1: Karyotype analysis of the OS-33 cell line shows several chromosomal 





Karyotype analysis of the OS-33 cell line shows that 13 out of 20 chromosomes are 
hyper-triploid aneuploidy. There were also well over 100 chromosomes and many broken 
chromosomal fragments, called satellite DNA, which confirm OS-33 an abnormal and 
human cancer cell line [14]. This complex karyotype is typical of a cancerous cell line 
with a p53 mutation commonly found in OS [15]. 
 







Figure 2: Western blot analysis of the pS6/S6 ratio indicates inhibition of the mTORC1 
pathway with increasing levels of rapamycin treatment. A) Qualitative measurements of 
Western blot analysis are displayed as imaged. B) The pS6/S6 ratio was analyzed and 





In order to better understand how rapamycin inhibits the mTORC1 pathway, we 






















Since mTORC1 is a kinase cascade pathway, the upregulation of mTORC1 will increase 
phosphorylation of a downstream target, S6 [16]. Therefore, increased levels of pS6 can 
be found when activity of mTORC1 is increased. With increasing rapamycin treatment, 
we see a smaller pS6 to S6 ratio. This indicates that the mTORC1 pathway is directly 
inhibited with increased rapamycin treatment in OS-33.  
 







Figure 3: Colony formation assay with 0, 0.1, and 1 ng/mL rapamycin treatment shows 




 Over a 14-day period, OS-33 cells were monitored for colony forming activity and 
imaged using a crystal violet stain. Results show that OS-33 has limited ability to form 
colonies and colony formation is further inhibited by increasing rapamycin treatment. It 
should be noted that these results are preliminary and further testing over a longer time 
period has potential to result in colony formation. 
 









Figure 4: Scratch assay (wound healing assay) with 1 ng/mL rapamycin treatment shows 




The general trend of migration and proliferation can be examined by a scratch assay, 
where a decrease in the width of the “wound” or “scratch” in the cells overtime indicates 
that OS-33 cells have proliferated or migrated. As shown in Figure 4, there was full 
wound closure in the cells with 0 ng/mL rapamycin treatment. Treatment of OS-33 with 1 
ng/mL rapamycin inhibits closure of the wound over time.  

















Figure 5: The capacity of OS-33 to migrate through a semi-porous membrane in a trans-
well system was inhibited by rapamycin treatment. A) There is a visible decrease in the 
number of cells which pass through to the chemoattractant in the bottom well as seen 
through microscope imaging (10X) between ethanol treatment (0 ng/mL) and rapamycin 
treatment (1 ng/mL). B) Quantitative analysis comparing ethanol (EtOH) and 1 ng/mL 
rapamycin (Rapa) treatment shows decreased trans-well migration. Ethanol treatment 
serves as a baseline for 100% migration which rapamycin treatment was compared to 




Migration in a trans-well assay is measured by the number of cells which have passed 
through the semi-porous membrane and are found on the bottom side of the cell culture 
insert containing the chemo-attractant at the time of staining. A decreased number of cells 
found in the chemo-attractant means that migration was inhibited. By comparing the 




























rapamycin and by quantifying the data with Cytation3, we can see that rapamycin 
inhibited migration significantly. The inhibition of migration mimics the ability for OS 
cells to travel through an extracellular matrix in vivo [17].  
 







Figure 6: The capacity of OS-33 to invade through a semi-porous membrane with a 
matrigel in a trans-well system was inhibited by rapamycin treatment. A) There is a 
visible decrease in the number of cells which pass through the matrigel to the 
chemoattractant in the bottom well as seen through microscope imaging (10X) between 
ethanol treatment (0 ng/mL) and rapamycin treatment (1 ng/mL). B) Quantitative 
analysis comparing ethanol (EtOH) and 1 ng/mL rapamycin (Rapa) treatment shows 
decreased trans-well invasion. Ethanol treatment serves as a baseline for invasion which 
rapamycin treatment was compared to fractionally and found significant (*P<0.05, 





























Similar to the migration assay, inhibition of invasion was qualitatively measured by 
images and quantitatively measured OD with the Cytation3 instrument. With 1 ng/mL 
rapamycin treatment, invasion was inhibited. This therefore indicates inhibition of the 
mTORC1 pathway by rapamycin treatment.  
 







Figure 7: Adipocyte differentiation assay of OS-33 cell line with 1 ng/mL rapamycin 




Over a 14-day period, cell lines were treated with an adipocyte-inducing medium and 1 
ng/mL rapamycin treatment or 100% ethanol. The purpose of this is to test the effects of 
rapamycin treatment on mesenchymal stem cell differentiation. Staining with Oil Red-O 
and Hematoxylin counter stain shows adipocyte formation. Lipid droplets appear in red. 
OS-33 cell differentiation capacity was inhibited with rapamycin treatment. 
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Quantification shows significant results and inhibition. (*P<0.05, **P<0.01, ***P 
<0.001). 
 







Figure 8: Osteoblast differentiation assay of OS-33 cell line with L2 control cell line 




Over 14 days, the two lines, OS-33 and L2 (control), were grown with and without 
osteoblast-inducing medium. Medium changes were completed every three days and 













mesenchymal stem cell differentiation as predicted, there was no differentiation in the 
OS-33 cell line.  
 







Figure 9: Osteoblast differentiation assay of the OS-33 and C2C12 cell lines with BMP-2 




After obtaining no differentiation with the osteoblast-inducing medium in the OS-33 cell 
line, 1 µL/mL of the reagent BMP-2 was added to the medium in efforts to differentiate 
stem cells into osteoblasts. C2C12 was used as a control cell line. After staining with 













shown in red. The OS-33 cells showed limited differentiation from mesenchymal stem 
cells into osteoblasts.  
 







Figure 10: Cellular proliferation assay at 48 hours with OS-33 and increasing 





Results of the cell proliferation analysis for OS-33 with rapamycin treatment show a 
general decrease in proliferation as the concentration of rapamycin treatment increases; 
however, there showed to be no significant levels of inhibited proliferation. Best results 
were obtained at 48 hours of treatment with media changes every 24 hours. The IC50 

























Figure 11: Cellular proliferation assay at 48 hours with OS-33 and increasing 





Results were obtained at 48 hours, with a media change at the 24-hour mark. As 
expected, increasing doxorubicin treatment concentrations correlated with decreased 
proliferation. A significant decrease in proliferation was found at 50 µM of doxorubicin 






























Figure 12: Cellular proliferation assay with OS-33 and increasing doxorubicin and 
rapamycin constant-ratio combination drug therapy using CCK-8 for quantification 




After obtaining significant results for both the rapamycin and doxorubicin cell 
proliferation assays, a combination therapy technique was implemented in which a 1:2 
ratio of doxorubicin to rapamycin treatment was tested. Results showed that rapamycin 
and doxorubicin held significant synergistic effects in prohibiting the proliferation of the 































Conclusion and Future Directions 
 
In this study, we discovered that the novel OS-33 cell line has capabilities to 
proliferate, migrate, and differentiate; however, these capabilities can be limited by 
inhibiting the mTORC1 pathway with use of rapamycin. A karyotype analysis of the OS-
33 cell line displayed severe abnormalities in the chromosomes and provided support that 
this is a cancerous cell line originated from human osteosarcoma. Western blot analysis 
quantified the inhibition of mTORC1 by displaying the decreased pS6/S6 ratio with 
increasing rapamycin treatments on the OS-33 cell line, implicating a very high level 
activity of mTORC1 signaling pathway in OS-33 cells. While the cell line showed 
limited capabilities for colony formation, both with and without rapamycin treatment, it 
did show decreasing ability to proliferate and migrate with rapamycin treatment in a 
scratch assay. This led into further investigation of migration and invasion qualities of the 
cell line. In both the migration and the invasion assays, the OS-33 cell line showed the 
ability to move through wells towards the chemoattractant. Next, the ability to 
differentiate was tested with both adipocyte-inducing medium and osteoblast-inducing 
medium. The ability for OS-33 to differentiate into adipocytes was capable and was 
inhibited with rapamycin treatment. This indicates stem cell potential to differentiate the 
cancerous cells into normal, fat tissue. However, it should be noted that the formation of 
lipid droplets was not normal of a classic adipocyte differentiation assay. In the future, 
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use of adipocyte markers could give more clear results. There was no significant 
differentiation of the OS-33 cell line into osteoblasts until the reagent BMP-2 was added. 
Upon adding this reagent, there were significant levels of increased deposition of calcium 
compounds, which were detected by Alizarin red S staining. In order to examine drug 
sensitivity of OS-33, cellular proliferation assays were conducted using rapamycin, 
doxorubicin, and a combination therapy treatment. While neither the rapamycin or 
doxorubicin showed significant results alone (with the exception of 50 µM of 
doxorubicin), when combined at 1:2 doxorubicin/rapamycin ratio, they were shown to 
significantly inhibit proliferation by inhibition of the mTORC1 pathway.  
The importance of this study as a whole shows how a novel osteosarcoma cell line 
is directly affected by targeting the mTORC1 pathway. Using rapamycin, a known 
mTORC1 inhibitor, inhibited the migrating, invading, and differentiating capabilities of 
OS-33. Furthermore, when doxorubicin is added to the rapamycin treated cells there is a 
synergistic effect of combining two inhibitors of proliferative capabilities. The data 
confirms that the cancerous OS-33 cell line is dependent on the mTORC1 pathway, 
which is consistent with previous studies highlighting the importance of using the 
mTORC1 signaling pathway as a therapeutic marker in cancerous cell lines [18]. 
Together, our study, which uses a novel OS cell line, will help others understand the 
importance of the mTORC1 signaling pathway and provide a new tool to study OS 
biology in general, as well as to find potential drugs targeting OS cells.  
As with every study, error and alternative explanations should always be 
considered as a possibility. This study was limited to a 3-month period of work. The 
mTORC1 inhibition by rapamycin and doxorubicin was only studied on the OS-33 
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osteosarcoma cell line in this study. Experiments are also limited to the accuracy of cell 
Countess instrument and the Cytation3. It should also be noted that imaging could be 
unintentionally biased towards the results of experiment with limited numbers of 
experiments. Experiments such as the colony formation assay could show differing 
results over a longer time-period. Thus, those data presented in this thesis are very 
preliminary and need to be further studied.   
The results provided in this paper could provide preliminary pre-clinical evidence 
for future clinical trials using rapamycin in osteosarcoma patients in combination with 
other drugs. This holds the potential to change the options for future patient treatment. 
Specifically, we hope that treatment methods can target metastasis and prevent spreading 
or growth of tumors. 
Using OS-33 cells, we plan to further test the effects of combination therapy using 
doxorubicin and rapamycin treatments. We hope to implement combination therapy 
treatments into other experiments to see how it would affect results from Western blot 
analysis, trans-well migration and invasion, scratch assays, and colony formation assays. 
These experiments would give a greater understanding of the synergistic effects of the 
two drug treatments. Results of combination therapy could provide pre-clinical evidence 
for future clinical trials, which could change the options for human patient treatment. We 
will also implement nude-mice xenografts and treatment to test inhibition of the 
mTORC1 pathway and cancer proliferation in vivo. By using immune-deficient mouse 
models, future studies may implement the OS-33 cell line and test the effects of 
combination therapy. This warrants with our continuing use of the OS-33 cell line. 
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The results obtained in this study played a major role in defining the novel OS-33 
osteosarcoma cell line. Through various experiments, we explored the role of mTORC1 
signaling pathway plays in osteosarcoma proliferation and migration. This will help us to 
explore new possible combination therapy treatments. The intention of these treatments is 
to prevent metastasis, which is more resistant to conventional cancer therapies and is 
more difficult to remove than a tumor [19]. By better understanding osteosarcoma as a 
cancer model, metastasis of the cancer, and the mTORC1 pathway, we are unlocking 
improved possible treatment methods for patients. 
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